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Abstract
Background: Interventions to improve care for persons with chronic medical conditions often
use quality of life (QOL) outcomes. These outcomes may be affected by coexisting (comorbid)
chronic conditions as well as the index condition of interest. A subjective measure of comorbidity
that incorporates an assessment of disease severity may be particularly useful for assessing
comorbidity for these investigations.
Methods: A survey including a list of 25 common chronic conditions was administered to a
population of HMO members age 65 or older. Disease burden (comorbidity) was defined as the
number of self-identified comorbid conditions weighted by the degree (from 1 to 5) to which each
interfered with their daily activities. We calculated sensitivities and specificities relative to chart
review for each condition. We correlated self-reported disease burden, relative to two other well-
known comorbidity measures (the Charlson Comorbidity Index and the RxRisk score) and chart
review, with our primary and secondary QOL outcomes of interest: general health status, physical
functioning, depression screen and self-efficacy.
Results: 156 respondents reported an average of 5.9 chronic conditions. Median sensitivity and
specificity relative to chart review were 75% and 92% respectively. QOL outcomes correlated
most strongly with disease burden, followed by number of conditions by chart review, the Charlson
Comorbidity Index and the RxRisk score.
Conclusion: Self-report appears to provide a reasonable estimate of comorbidity. For certain
QOL assessments, self-reported disease burden may provide a more accurate estimate of
comorbidity than existing measures that use different methodologies, and that were originally
validated against other outcomes. Investigators adjusting for comorbidity in studies using QOL
outcomes may wish to consider using subjective comorbidity measures that incorporate disease
severity.
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Background
The goal of caring for persons with chronic medical con-
ditions is frequently to maximize quality of life (QOL)
rather than to 'cure' illness. Therefore interventions to
improve processes of care for this population often assess
QOL outcomes such as physical functioning, overall
health status, and emotional well being. These outcomes
are, by definition, subjective. The values assigned to these
outcomes are most meaningful to the patients themselves.
However, these subjective outcomes have been shown to
correlate with mortality, health care utilization, job loss,
and many other more 'quantifiable' outcomes [1-3].
The outcomes of a chronic condition may be affected by
coexisting (comorbid) chronic conditions as well as the
index condition of interest and analyses must adjust for
this effect of comorbidity. Multiple instruments have been
developed and validated to quantify comorbidity for pur-
poses of statistical adjustment and clinical decision mak-
ing. The majority of these use medical record review or
administrative data as sources of information; observa-
tion during clinical encounters and self report have also
been used for this purpose. These instruments have pri-
marily been validated against 'objective' health outcomes
such as mortality, length of stay, and cost of care [4-13].
We are aware of two such instruments that have been val-
idated against QOL outcomes [5,14]. In addition, many
of these instruments were designed for use in hospitalized
patients or populations characterized by specific illnesses.
Self-reported information about comorbidity and the bur-
den it imposes can provide information about the concur-
rent impact of multiple disease states on QOL outcomes.
Self-reported comorbidity information is also efficient in
studies in which other information, such as QOL out-
comes, is collected by survey. Instruments designed to
assess comorbidity by self-report have reported significant
correlations between comorbidity score and utilization,
QOL, mortality and hospitalization [15-20].
It is important to incorporate assessment of disease sever-
ity into comorbidity measurement [6]. Some self-report
instruments incorporate various weighting systems for
this purpose and two of these have been validated in hos-
pitalized populations [15,18]. We have developed a self-
report instrument that incorporates disease severity by
quantifying the respondent's subjective 'disease burden'
which we define as the number of self-identified comor-
bid conditions weighted by the degree to which each con-
dition limits daily activity. We hypothesized that a
subjective measure of comorbidity such as this may be
more strongly correlated with QOL outcomes than meas-
ures of comorbidity previously validated against other,
more objective, health outcomes.
Our goals in this investigation were to validate this newly-
developed instrument against a presumed 'gold standard'
of chart review, and to conduct an initial comparison of
this instrument with other well known measures of
comorbidity (chart review of number of conditions, the
Charlson Comorbidity Index and the RxRisk score) by
correlating these measures with selected QOL outcomes.
Methods
Study setting and sample selection
The study setting was a Health Maintenance Organization
(HMO) in the United States that provides primary, spe-
cialty and hospital care for persons of all ages. Due to the
use of an electronic medical record, both primary and spe-
cialty providers can enter diagnoses and assessments into
a single patient record. Participants were selected from a
stratified random sample of HMO members age 65 or
older with 0 (8%), 1 (10%), 2 (12%), or 3 or more (69%)
chronic medical conditions. We sampled this age group
based on the high prevalence of comorbid conditions in
older adults [21]. The stratification was performed with a
modified version of the RxRisk comorbidity assessment
instrument that uses administrative pharmacy data to
determine an estimated disease count [4]. As one of the
goals of our investigation was to assess issues of impor-
tance to persons with multiple comorbidities, we over-
sampled members with a greater number of chronic
conditions. Due to the pilot nature of the study, we used
consecutive random sampling in increments of single
mailings until we had sufficient sample size to evaluate
the instrument. We calculated that we would need a sam-
ple size of 139 for an expected proportion (sensitivity and
specificity) of 0.90 to have a 95% confidence interval with
a total width of 0.10.
Instrument development
We searched the literature to determine the health condi-
tions most frequently assessed in measuring comorbidity
[4,5,7,17,22-26]. From this we assembled a list of 25 com-
mon chronic conditions and coupled it with a scale that
asked respondents to report for each condition a) whether
they had the condition, and b) if so whether it interfered
with their daily activities "not at all' (a weight of 1) to "a
lot" (a weight of 5). These responses then provided a
measure of 'disease burden' (comorbidity) that resulted
from weighting each reported condition by the degree of
limitation. These conditions are listed in Table 2. Depres-
sion is absent from the list of morbidities as it was
assessed as a separate outcome measure. As there is a
known correlation between comorbidity and physical
dimensions of QOL, we chose overall health status and
physical functioning as our primary outcomes of interest
[14]. We also investigated depression and self-efficacy as
secondary outcomes important in caring for persons with
multiple morbidities.Health and Quality of Life Outcomes 2005, 3:51 http://www.hqlo.com/content/3/1/51
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Survey administration
We pre-tested the instrument for clarity and ease of com-
pletion with volunteers who were age 65 or older and had
more than one chronic medical condition. Pre-testing was
conducted in one-on-one interviews in which the volun-
teer completed the survey and then provided detailed
feedback to the interviewer on the content and compre-
hension of the measure. Any recommended changes were
incorporated into the subsequent version of the instru-
ment. It was then mailed to respondents as a component
of another pilot survey that assessed potential barriers to
the medical self-care process. The complete questionnaire
included validated questions that assessed physical func-
tioning and general health status, a depression screen, and
an adapted and concurrently validated assessment of gen-
eral self-efficacy. We used the physical functioning meas-
ure and the general health status single question from the
Short-Form 36®, the depression screen from the Behavio-
ral Risk Factor Surveillance System, and a concurrently
validated adaptation of the general self-efficacy scale (our
coefficient alpha = 0.76) [1,27-29]. We used these assess-
ments as our primary and secondary QOL outcomes of
interest for the current investigation. The investigation
was approved by the Institutional Review Board of the
participating HMO and informed consent was obtained
from all participants.
Comparison with chart review
We compared each participant's responses with diagnoses
listed in their electronic medical record. We reviewed
assessments from all outpatient encounters over the two
years preceding the survey and accepted at least two chart-
documented assessments of a chronic condition as an
active diagnosis. Requiring two rather than one chart diag-
nosis may reduce the sensitivity of self-report [30]. How-
ever, we based our decision on the assumption that a
recurrence of a chronic diagnosis would reasonably have
been communicated to the patient, and therefore he or
she might be expected to list that diagnosis in their
response to our survey. Either two recorded outpatient
diagnoses or one inpatient diagnosis have been suggested
as a reasonable standard for a confirmed diagnosis [31].
In our chart review, we also counted previously docu-
mented chronic conditions that were likely to persist (e.g.
Table 2: Sensitivity and Specificity of Self-Report Relative to Chart Review (N = 1511)
Prevalence
Medical condition2 Mean Self-Report 
Disease Burden
Self-Report n 
(%)
Chart Review n 
(%)
Sensitivity 
(%)
Specificity 
(%)
Angina/coronary artery disease 2.2 19 (12) 39 (25) 41 97
Asthma 2.7 20 (13) 12 (8) 100 94
Back pain 3.0 61 (39) 37 (24) 92 77
Bronchitis, chronic/COPD 3.1 20 (13) 20 (13) 70 96
Cancer (within the past 5 yrs) 1.7 11 (7) 20 (13) 55 100
Cholesterol, elevated 1.6 81 (52) 78 (50) 89 85
Colon problem (e.g., diverticulitis, irritable bowel) 2.8 21 (14) 12 (8) 75 92
Congestive heart failure 2.5 23 (15) 23 (15) 74 96
Diabetes 2.2 31 (20) 32 (21) 88 98
Hard of hearing 2.6 75 (48) 32 (21) 81 61
Hypertension 1.8 95 (61) 103 (66) 84 83
Kidney disease 2.0 6 (4) 17 (11) 35 100
Nerve condition 3.4 9 (6) 15 (10) 47 99
Osteoarthritis 2.8 72 (46) 69 (44) 73 75
Osteoporosis 2.1 30 (19) 22 (14) 86 92
Overweight 2.4 70 (45) 28 (18) 96 66
Poor circulation (e.g., peripheral vascular disease) 3.0 44 (28) 14 (9) 93 78
Rheumatic disease, other 3.2 5 (3) 4 (3) 75 99
Rheumatoid arthritis 3.2 25 (16) 4 (3) 75 86
Stomach problem (e.g., gastritis, peptic disease) 2.3 46 (30) 40 (26) 75 86
Stroke 2.4 16 (10) 20 (13) 60 97
Thyroid disorder 1.5 39 (25) 41 (26) 90 98
Vision problem 2.3 98 (63) 109 (70) 78 72
1 Total N = 156, 151 participants reported 1 or more conditions.
2 For most conditions, an example or two were provided to illustrate the diagnostic category. For example, 'other rheumatic disease" was 
presented as "rheumatic disease such as fibromyalgia or lupus"; and "nerve condition" was presented as "nerve condition such as Parkinson's disease 
or multiple sclerosis."Health and Quality of Life Outcomes 2005, 3:51 http://www.hqlo.com/content/3/1/51
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hearing loss). We did not count diagnoses of chronic
problems that had been surgically corrected and required
no further management (e.g. cataract surgery).
Comparison with other measures of comorbidity
In addition to calculating comorbidity with our instru-
ment, for each respondent we quantified level of comor-
bidity using two other validated comorbidity
measurement tools. These two methods were the RxRisk
score and the Charlson comorbidity index [4,7]. We chose
these based on both their common use and the contrast
they provided in methodologies since they use different
methods of data collection and have been validated
against different outcomes. The RxRisk score is a measure
of comorbidity that incorporates age, gender, health
insurance benefit status and an RxRisk category based on
diagnoses derived from administrative pharmacy data. It
was originally developed and validated to identify chronic
conditions and to predict cost of health care, and subse-
quently revised to assess disease burden in certain popu-
lations [4,32]. We used administrative pharmacy data to
apply the RxRisk tool to our study population. The Charl-
son comorbidity index is a widely used comorbidity
measure that was originally developed to predict one-year
mortality following hospitalization. The score is based on
chart review for specified diagnostic criteria. It has been
subsequently adapted and revalidated to assess longer
term mortality, disability, hospital readmission and
length of stay and has been revised into formats that uti-
lize either ICD-9 diagnosis codes or questionnaire [6-
8,25]. We calculated the Charlson comorbidity score
using chart review.
Statistical methods
We calculated sensitivity and specificity for each condition
using the chart report as the 'gold standard.' We also cal-
culated sensitivity and specificity for each participant to
indicate the percent of positive and negative conditions
on which the respondent and chart agree relative to the
total positive or negative conditions in the chart. Thus
specificity and sensitivity by condition reflect respondents'
overall tendency to accurately report a given condition rel-
ative to chart report, and sensitivity and specificity by par-
ticipant reflect respondents' overall tendency to accurately
report on all of their conditions in comparison to the gold
standard of chart review. (Note that sensitivity and specif-
icity analyses used self-reported presence or absence of
conditions for comparison rather than the weighted dis-
ease burden score.) In order to further compare self-
reported disease burden with our 'gold standard' of chart
review, for each condition we entered self-reported dis-
ease burden followed by chart report of that condition
into limited logistic regression models to assess the rela-
tive contributions of each of these independent variables
to the predictive accuracy of the model for each of our out-
come measures [33].
We calculated Spearman correlations between disease
burden from the new instrument, disease count by chart
review, the Charlson index and the RxRisk score, with our
QOL outcomes of interest: measures of overall health sta-
Table 1: Characteristics of study population (N = 156)
Characteristic Number (%)
Age (mean, range) 75.0, 67–94
Gender
Male 75 (48.1)
Female 77 (49.4)
Missing, chose not to answer 4 (2.6)
Marital status
Married 101 (64.7)
Widowed 33 (21.2)
Divorced/separated 18 (11.5)
Missing, chose not to answer 4 (2.6)
Education level
Did not graduate high school 16 (10.3)
High school graduate 42 (26.9)
Some college 42 (26.9)
College graduate 20 (12.8)
Post-college 31 (19.9)
Missing, chose not to answer 5 (3.2)
Household income (mean category)
Less than $15,000 22 (14.1)
$15,000–30,000 38 (24.4)
$30,000–45,000 29 (18.6)
$45,000–60,000 20 (12.8)
$60,000–75,000 12 (7.7)
$75,000–90,000 1 (0.6)
More than $90,000 5 (3.2)
Missing, chose not to answer, don't know 29 (18.6)
Race
Caucasian 142 (91.0)
African-American 1 (0.6)
Other 7 (4.5)
Missing, chose not to answer 6 (3.8)
Hispanic ethnicity
Yes 5 (3.2)
No 131 (84.0)
Missing, chose not to answer 20 (12.8)
Health status
Excellent 6 (3.9)
Very Good 43 (27.6)
Good 67 (43.0)
Fair 30 (19.2)
Poor 4 (2.6)
Missing 6 (3.9)
Level of Comorbidity (mean, range of each)
Number of Self-Reported Conditions 5.9, 0–16
Self-Reported Disease Burden* 13.9, 0–51
*Total score of limitations due to conditions (Sum of weights from 1 
to 5 for each condition present).Health and Quality of Life Outcomes 2005, 3:51 http://www.hqlo.com/content/3/1/51
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tus, physical functioning, positive depression screen, and
level of self-efficacy.
Results
After two consecutive single mailings, 157 individuals
completed the survey. The response rate of 28% was
obtained without the use of strategies typically employed
to increased response, such as multiple mailings or more
active follow-up. Characteristics of respondents are noted
in Table 1. Mean age was 75, health status ranged from
excellent to poor and respondents reported an average of
5.9 chronic conditions. Respondents did not differ from
non-respondents with regard to age, gender, number of
chronic conditions (as estimated by the initial screen with
the RxRisk instrument), or duration of HMO
membership.
One hundred fifty-one respondents reported at least one
of the conditions and 6 reported none. In analyses by con-
dition, median sensitivity of patient report of a condition
relative to a 'gold standard' of chart review was 75%
(range 35% to 100%) and median specificity was 92%
(range 61% to 100%). In analyses by respondent, sensitivi-
ties (agreement on number of conditions positive relative
to chart review) ranged from 14% (n = 1) to 100% (n =
53); the median was 83%. Sensitivities were not calcu-
lated for the ten respondents who did not agree with the
chart on any conditions, including those who agreed with
their medical record that they had none of the conditions
(n = 2). Specificities by respondent ranged from 59% (n =
1) to 100% (n = 34); the median was 91%. Sensitivity and
specificity of self-report of each condition relative to chart
review are reported in Table 2. (Not included on the table
are results for 2 of the original 25 conditions: liver disease
and alcoholism. Two respondents and one separate chart
reported alcohol abuse, and no respondents or charts
reported liver disease.)
In order to assess the relative contributions of self
reported diseases and disease count by chart review to the
outcomes of general health status and physical function-
ing, we entered these two variables into limited logistic
regression models. In these models containing only these
two variables, the predictive accuracy of the model (as
measured by the c-statistic) was not significantly different
using each of the two variables, implying comparable con-
tributions of either measure. C-statistics for overall health
status ranged from 0.521 ("other rheumatic disease) to
0.669 ("osteoarthritis"); and for physical functioning
ranged from 0.515 ("other rheumatic disease") to 0.679
("overweight").
QOL outcomes of interest correlated most strongly with
self-reported disease burden, followed by number of con-
ditions by chart review, self-reported number of condi-
tions, the Charlson index score and the RxRisk score.
Although all measures of comorbidity except the RxRisk
score showed comparable p values (p <= 0.001) for the
outcomes of health status and physical functioning, the
correlations for disease burden were significantly stronger
than those for self-reported number of conditions or
Charson comorbidity score for these outcomes. Table 3
lists these correlations for our primary outcomes of inter-
est – overall health status and physical functioning – and
our secondary outcomes of positive screen for depression
and self-efficacy.
Discussion
It is important to incorporate assessment of comorbidity
into studies involving QOL outcomes for persons with
chronic medical conditions, as coexisting conditions may
substantially affect outcomes of interest such as physical
functioning, overall health status, depression and self-effi-
cacy. In our study population, patients with multiple
chronic medical conditions accurately reported a majority
of common comorbid conditions relative to chart review.
In addition, they were aware of most of their own diag-
noses. Furthermore, self-reported disease burden corre-
lated well with QOL outcomes, and correlated more
strongly than did the two other measures of comorbidity
Table 3: Correlations Between Measures of Comorbidity and QOL Outcomes (N = 1562)
Self reported 
disease burden1
Chart review number 
of conditions
Self reported number 
of conditions3
Charlson comorbidity 
score [7]
Rx-risk score [4]
Overall health status* (n = 150) 0.60 p < 0.001 0.56 p < 0.001 0.477 p < 0.001 0.48 p < 0.001 0.17 P = 0.037
Physical functioning* (n = 137) -0.63 p < 0.001 -0.52 p < 0.001 -0.482 p < 0.001 -0.41 p < 0.001 -0.18 p = 0.035
Depression screen* (n = 153) -0.29 p < 0.001 -0.25 p = 0.002 -0.240 p = 0.003 -0.12 p = 0.140 -0.05 p = 0.559
Self-efficacy* (n = 145) -0.32 p < 0.001 -0.22 p = 0.008 -0.305 p < 0.001 -0.14 p = 0.096 0.10 p = 0.234
* For health status, a higher score implies worse perceived health; for other outcomes, a higher number implies a better functioning, less depression 
or greater self-efficacy.
1 Total score of degree of limitation due to each positive condition (1 = not at all to 5 = a lot).
2 Due to missing scale scores, total n ranged from 137 (physical activity) to 154 (social activity).
3 Number of conditions from the list that were positively reported by the respondent.Health and Quality of Life Outcomes 2005, 3:51 http://www.hqlo.com/content/3/1/51
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that we used for comparison. This is consistent with our
hypothesis that, for investigations using QOL outcomes, it
is most appropriate to adjust for comorbidity using a sub-
jective measure of comorbidity.
Previous investigations that have compared self-report
with administrative data reported 59–79%, 72–73%, and
78–83% agreement on diagnoses of hypercholestero-
lemia, diabetes, and hypertension respectively; and 56%
and 69% agreement on stroke and myocardial infarction
[30,34]. In our investigation we expanded the number of
conditions for comparison to 23 and additionally
assessed respondents' tendencies to accurately report all of
their own conditions. Certain diagnoses were reported
with high levels of sensitivity and specificity, while others
were not.
A sensitivity greater than specificity may be due to either
'over-reporting' by participants or 'under-reporting' in the
chart. Examples from our list included asthma, back pain,
overweight and hard-of-hearing. We suspect that, for the
first case, some participants reported COPD as asthma.
For the remaining cases, we suspect that the conditions
were under-reported in the chart – either because they had
not been brought to medical attention or because they
had not been assessed as isolated problems in the context
of medical visits during the period covered by the chart
review.
Sensitivity was substantially less than specificity for
angina, nerve conditions, cancer and kidney disease.
Although there may be a tendency to under-report chronic
conditions, and respondents are more likely to report con-
ditions with more severe symptoms [17,35]; we re-
reviewed charts of persons with these diagnoses to see if
we could determine the cause of the discrepancies. From
these repeat chart reviews, we concluded that these dis-
crepancies were due to wording based more on symptoms
than diagnosis (angina), under-reporting of conditions
with stable or few symptoms (renal and neurological),
and possible perceptions of cure or remission after acute
treatment (cancer). In addition we analyzed the demo-
graphic and health characteristics (from Table 1) of
respondents for each of these four conditions to see if any
demographic or disease characteristics were likely to pre-
dict a low agreement with chart review and found no
patterns.
In our assessments of sensitivity and specificity, we
assumed that the presence of a diagnosis in the chart was
a 'gold standard' – an assumption that may not be entirely
accurate. We suspect that diagnoses for which there are
obvious medical treatments – especially medications – are
more likely to be recorded in the chart. Chart diagnoses
may be less accurate for conditions for which a person is
less likely to seek (or for which a provider is less likely to
offer) specifically biomedical solutions.
We found a high correlation between our measure of dis-
ease burden and our QOL outcomes of interest, as com-
pared to lower correlations between two other
comorbidity indices and these same outcomes. However,
the correlations between the other comorbidity indices
and health status and physical functioning were also sig-
nificant and have been noted previously [36]. The correla-
tions between the Charlson and RxRisk scores and our
secondary outcomes of interest (depression screen and
self-efficacy) were not significant. Based on the pattern of
these associations, we suggest that assessment of comor-
bidity is a function of the outcome of interest, the popu-
lation studied, and the different (subjective versus
objective) aspects of comorbidity measured by each
instrument. The effect of comorbidities on QOL outcomes
may be most accurately assessed when subjective meas-
ures are used to adjust for comorbidity. In contrast, for sit-
uations in which mortality, for example, is the outcome of
interest, comorbidity should be assessed using instru-
ments that have been developed for that purpose. These
suggestions are consistent with the notion that 'complete'
measurement of all health states requires both self-
reported and objectively reported measures [37].
It is certainly possible that one comorbidity measure may
work for many situations. Other self-report instruments
have been shown to predict mortality and hospitalization
in addition to QOL [15,16,18]. We are also aware of at
least two investigations in which comorbidity measured
by chart review correlated with QOL outcomes [5,14]. The
two instruments with which we compared our own instru-
ment use different methodologies and were originally
developed to assess comorbidity in studies investigating
the objective outcomes of mortality and cost of care
respectively [4,7]. The Charlson index has been subse-
quently validated against length of stay, post operative
complications, discharge to nursing home, disability, hos-
pital readmission and hospital charges [6,8,38-40]. The
RxRisk score has subsequently been adapted and vali-
dated against administrative data on diagnoses and dis-
ease burden in certain populations [4,32]. Our
investigation adds to the growing body of knowledge on
measuring comorbidity by highlighting the different
results that may be obtained when using different meth-
odologies to adjust for comorbidity in studies assessing
QOL outcomes.
We did not incorporate additional measures of comorbid-
ity, such as those that use administrative data into our
analysis [8,12,13]. Previous comparative studies suggest
that chart-review-based measures may be slightly more
accurate than administrative data-based comorbidityHealth and Quality of Life Outcomes 2005, 3:51 http://www.hqlo.com/content/3/1/51
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measures in predicting objective outcomes such as mor-
tality and length of hospital stay [6,38,41]. Further inves-
tigation is necessary to assess association of comorbidity
measured by administrative data with QOL outcomes.
As with any initial validation effort, the generalizability of
our conclusions is limited by the characteristics of the
population studied – a relatively small HMO population
aged 65 years or older. It is possible that this population
is relatively 'well-educated' regarding the number and
type of their medical conditions. If so, some of the sensi-
tivities we report may be at the upper end of the spectrum
that may be anticipated from self-report. In addition, we
terminated the sampling process when we attained a sam-
ple size sufficient to test our primary hypothesis, without
maximizing response rate. Thus, the findings in this sam-
ple may not represent the associations of a broader popu-
lation. Although respondents did not differ significantly
from non-respondents on RxRisk comorbidity score,
more motivated or knowledgeable participants may have
been more likely to respond promptly to our survey. Cor-
relations and sensitivities could be lower when examined
in a less motivated population or those with a lower
knowledge base. Specifically, self-report may be less relia-
ble in the geriatric sub-population that may suffer from
cognitive impairment. Additional validation studies will
be required in order to assess the usefulness of this instru-
ment in other populations and for different QOL and
other outcomes. We anticipate that these changes will
strengthen our results for sensitivity in comparison to
chart review and that they will not change the overall cor-
relations with our outcomes of interest.
Disease burden (as we defined it) may in itself constitute
a substantial portion of any patient's assessment of health
status and physical functioning. Our incorporation of per-
ceived limitation into a disease count may be similar to
other investigations that have coupled a simple disease
count with a health status measure such as the SF-36® and
found that doing so strengthened the relationship
between comorbidity and utilization and mortality
[16,19]. However, models that attempt to explain the rela-
tionship between symptom burden, overall quality of life
and physical functioning note that these outcomes are
also affected by environmental characteristics, individual
personality, expectations, values, and social and psycho-
logical supports [42,43]. What we refer to as disease bur-
den explains part, but not all, of our QOL outcomes as is
illustrated by the values of our c-statistics. To the extent
that investigations that use QOL outcomes concentrate on
participants with one index condition and need to adjust
for comorbidities, a subjective measure of disease burden
using self-report may be an accurate way to account for
the effect of other coexisting conditions with regard to
that outcome.
Finally, depression is both an important potential comor-
bidity for anyone with chronic illness as well as an equally
important component of the QOL outcome of emotional
well being. We chose to treat it as the latter. As depression
severity independently contributes to general QOL over
and above other coexisting chronic illness, we suspect that
including depression on our list of conditions would have
increased the strength of correlations between self-
reported disease burden and general health status [44,45].
Conclusion
Assessing comorbidity is relevant to investigations of pop-
ulations with multiple medical conditions and should be
incorporated into the associated analyses. Not only is self-
report likely to give a reasonable estimate of comorbidity,
for investigations using QOL outcomes, self-reported dis-
ease burden (or other subjective assessments of comor-
bidity) may provide a more accurate comorbidity
adjustment than measures that have been validated
against other outcomes. If this finding is confirmed by
additional investigation, subjective measures of comor-
bidity that incorporate disease severity should be added to
QOL assessments for populations with high rates of
comorbidity.
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